Pancreatic insulinoma
disease diseaseOn this page
Also known as adenoma, beta celladenoma, beta-celladenomas, beta-cellbeta cell tumorbeta cell tumourbeta-cell adenomabeta-cell adenomasbeta-cell tumorbeta-cell tumorsbeta-cell tumourbeta-cell tumoursinsulin-producing tumour of islet cellsinsulinomainsulinoma tumor suppressor GENE locusinsulinoma tumour suppressor GENE locusInsulinomasinsulomaInsulomastumor, beta-cell
Summary
Pancreatic insulinoma (MONDO:0024677) is a disease and 35 clinical trials. Top therapeutic interventions include fluorodopa f 18, edotreotide gallium ga-68, and gefitinib. A subtype of pancreatic insulin-producing neuroendocrine tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 35
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pancreatic insulinoma |
| Mondo ID | MONDO:0024677 |
| MeSH | D007340 |
| DOID | DOID:3892 |
| ICD-11 | 193813168 |
| NCIT | C95598 |
| SNOMED CT | 302822000 |
| UMLS | C0021670 |
| MedGen | 43907 |
| GARD | 0025458 |
| MedDRA | 10022498 |
| Is cancer (heuristic) | no |
Also known as: adenoma, beta cell · adenoma, beta-cell · adenomas, beta-cell · beta cell tumor · beta cell tumour · beta-cell adenoma · beta-cell adenomas · beta-cell tumor · beta-cell tumors · beta-cell tumour · beta-cell tumours · insulin-producing tumour of islet cells · insulinoma · insulinoma tumor suppressor GENE locus · insulinoma tumour suppressor GENE locus · Insulinomas · insuloma · Insulomas · pancreatic insulinoma · tumor, beta-cell (+1 more)
Data availability: 1 HPO phenotype · 2 cell lines.
Disease family
This is a subtype of pancreatic insulin-producing neuroendocrine tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › pancreatic neuroendocrine tumor › pancreatic insulin-producing neuroendocrine tumor › pancreatic insulinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Bevacizumab | Phase 2 |
| Temsirolimus | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 35.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 13 |
| PHASE2 | 12 |
| PHASE1 | 6 |
| EARLY_PHASE1 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01824875 | PHASE2 | ACTIVE_NOT_RECRUITING | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors |
| NCT00075439 | PHASE2 | COMPLETED | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
| NCT00084461 | PHASE2 | TERMINATED | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors |
| NCT00131911 | PHASE2 | COMPLETED | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
| NCT00454363 | PHASE2 | COMPLETED | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer |
| NCT01525082 | PHASE2 | COMPLETED | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors |
| NCT02031536 | PHASE2 | TERMINATED | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery |
| NCT02108782 | PHASE2 | WITHDRAWN | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors |
| NCT02259725 | PHASE2 | COMPLETED | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors |
| NCT02273752 | PHASE2 | TERMINATED | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer |
| NCT03053284 | PHASE2 | WITHDRAWN | Pasireotide in Hyperinsulinemic Hypoglycemia |
| NCT03189953 | PHASE1/PHASE2 | COMPLETED | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH |
| NCT04915144 | PHASE2 | WITHDRAWN | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs |
| NCT02021604 | PHASE1 | RECRUITING | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma |
| NCT00004074 | PHASE1 | COMPLETED | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
| NCT00655655 | PHASE1 | COMPLETED | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors |
| NCT01204476 | PHASE1 | COMPLETED | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
| NCT02831179 | PHASE1 | WITHDRAWN | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor |
| NCT04979611 | PHASE1 | UNKNOWN | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma |
| NCT02560376 | EARLY_PHASE1 | UNKNOWN | 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis |
| NCT04185350 | EARLY_PHASE1 | UNKNOWN | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma |
| NCT05034783 | EARLY_PHASE1 | UNKNOWN | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients |
| NCT00001276 | Not specified | RECRUITING | Diagnosing and Treating Low Blood Sugar Levels |
| NCT01916148 | Not specified | AVAILABLE | 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia |
| NCT03583528 | Not specified | ACTIVE_NOT_RECRUITING | DOTATOC PET/CT for Imaging NET Patients |
| NCT05735912 | Not specified | ACTIVE_NOT_RECRUITING | EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT) |
| NCT06725693 | Not specified | RECRUITING | Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease |
| NCT00005910 | Not specified | COMPLETED | Laparoscopy to Remove Pancreatic Tumors (Insulinomas) |
| NCT00937079 | Not specified | COMPLETED | Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients |
| NCT02121366 | Not specified | UNKNOWN | EUS-guided Ethanol Ablation of an Insulinoma |
| NCT02431715 | Not specified | NO_LONGER_AVAILABLE | 18F-FDOPA PET in Neuroendocrine Tumours |
| NCT03930368 | Not specified | UNKNOWN | Application of Raw Corn Starch on Patients With Insulinoma |
| NCT04452396 | Not specified | TERMINATED | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia |
| NCT05523778 | Not specified | UNKNOWN | A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct |
| NCT07340437 | Not specified | COMPLETED | Clinical Study of 18F-Exendin-4 in Insulinoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUORODOPA F 18 | 4 | 3 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| GEFITINIB | 4 | 1 |
| OCTREOTIDE ACETATE | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| REGORAFENIB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SORAFENIB | 4 | 1 |
| VATALANIB | 3 | 2 |
| VELIPARIB | 3 | 2 |
| CIXUTUMUMAB | 2 | 1 |
| DOVITINIB LACTATE | 2 | 1 |
| EDODEKIN ALFA | 2 | 1 |
| LUTETIUM LU177 EDOTREOTIDE | 2 | 1 |
| CHEMBL4066465 | 0 | 1 |